Jan 7 (Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public offering (IPO) filing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results